HNB
FATE icon

Huntington National Bank’s Fate Therapeutics FATE Stock Holding History

Huntington National Bank’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-225
Closed -$1.07K – 3855
2023
Q2 		$1.07K Buy
+225
New +$1.24K ﹤0.01% 2159

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Huntington National Bank's FATE Position: Q3 2023 in Review

Huntington National Bank sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 225 shares — an estimated $1.07K sold.

Huntington National Bank first reported a position in FATE in Q2 2023 and held it in 1 quarter. The position peaked at $1.07K in Q2 2023. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

  • Huntington National Bank reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Huntington National Bank sold 225 Fate Therapeutics shares in Q3 2023, an estimated $1.07K.
  • Huntington National Bank first reported a position in Fate Therapeutics in Q2 2023 and held it in 1 quarter.
  • Huntington National Bank's Fate Therapeutics position peaked at $1.07K in Q2 2023.
  • 170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on Huntington National Bank's 13F filing for Q3 2023, filed 8 Nov 2023.